Exabis Library
Welcome to the e-CCO Library!
P592 Frequency and causes of prolongation of the induction course of tofacitinib in patients with ulcerative colitis in conditions of real clinical practice
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P592: Clinical evaluation of leukocytapheresis compared to vedolizumab in patients with Ulcerative Colitis with contraindications to anti-TNF-alpha: a single-centre experience
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P592: Costs savings associated with ferric maltol and the reduced use of intravenous iron based on real world data
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P592: Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P592: Efficacy of vedolizumab for induction and maintenance of clinical remission in ulcerative colitis: The UCLH experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P592: Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P592: Towards a Food Pharmacy: increased dietary quality reduces CRP and improves quality of life in IBD patients in remission
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P593 Predictors of steroid-resistance in severe colitis of inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P593: A national database study on colectomy and colorectal cancer in ulcerative colitis: what is the role of appendectomy?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P593: Biologicals and small molecule combotherapies: promising experience in refractory IBD patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P593: Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P593: Hospital resource use and cost associated with first-line anti-TNF therapy in patients with IBD in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapies
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P593: Impact of immunomodulating treatment modalities, active smoking and (repeated) COVID19 vaccination on S-antibody seroconversion in IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P593: Ustekinumab for the treatment of perianal Crohn’s disease. A real-world experience in a Spanish hospital
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P594 Increased levels of stress, anxiety and depression among patients with CD and UC
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P594: Bowel ultrasound is useful in predicting relapse in patients with Ulcerative Colitis in remission
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P594: Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn’s disease (CD)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P594: Predictors of non-response to repeated faecal microbiota transplantation in patients with therapy refractory ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P594: Ustekinumab treatment effectiveness in clinical practice – a multicentre retrospective review of long-term outcomes in Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P594: Utilisation of anti-TNF agents in phlegmonous Crohn’s disease: an Australian tertiary referral centre experience
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM